Spasticity Pharmacotherapy

Spasticity — velocity-dependent increase in muscle tone with hyperreflexia — results from upper motor neuron lesions and produces substantial disability in stroke, spinal cord injury, multiple sclerosis, cerebral palsy, and other conditions. Effective management requires assessing whether spasticity is global or focal, productive or disabling, and combining pharmacotherapy with physical therapy and (where appropriate) surgical interventions. This page covers spasticity pharmacotherapy from oral agents to intrathecal pumps.

Pathophysiology Relevant to Pharmacology

  • Upper motor neuron lesion → loss of inhibitory descending control.
  • Velocity-dependent stretch reflex enhancement.
  • Mechanisms targeted by drugs:
    • Pre/postsynaptic GABA-B (baclofen, intrathecal baclofen).
    • α2 adrenergic (tizanidine, clonidine).
    • GABA-A (benzodiazepines).
    • Direct muscle (dantrolene).
    • Neuromuscular junction (botulinum toxin).

When to Treat Spasticity

  • Disabling (interfering with function, hygiene, position).
  • Painful.
  • Risk of contractures, pressure injuries.
  • NOT productive (i.e., not providing support for transfers, ambulation).
  • Sometimes spasticity is useful — providing weight-bearing stiffness; treating it can worsen function.

Oral Antispasticity Medications

Baclofen

  • Mechanism: GABA-B agonist; presynaptic + postsynaptic inhibition.
  • Dose: 5 mg TID → 80 mg/day divided.
  • Onset: hours; half-life 3-4 hours.
  • Side effects: sedation, weakness, dizziness, nausea, lower seizure threshold.
  • Baclofen withdrawal: life-threatening; fever, rebound spasticity, hallucinations, seizures, autonomic crisis; emergency reinstatement of dose.
  • Particularly important for intrathecal baclofen patients with pump failure.
  • Renal dose adjustment.

Tizanidine

  • Mechanism: α2 adrenergic agonist; central + spinal inhibition.
  • Dose: 2 mg TID → 36 mg/day.
  • Side effects: sedation, hypotension, dry mouth, hepatic enzyme elevation (monitor LFTs).
  • Useful in patients who cannot tolerate baclofen.
  • CYP1A2 substrate; interactions with ciprofloxacin (markedly increases levels).

Dantrolene

  • Mechanism: peripheral; blocks ryanodine receptor → reduces Ca²⁺ release from sarcoplasmic reticulum.
  • Dose: 25 mg QID → 400 mg/day.
  • Side effects: hepatotoxicity (significant risk; LFT monitoring; black box); weakness, sedation, diarrhea.
  • Useful in spasticity of cerebral origin where central agents cause too much sedation.
  • Also: malignant hyperthermia treatment (IV).

Diazepam (and Other Benzodiazepines)

  • Mechanism: GABA-A allosteric modulator.
  • Effective but limited by sedation, cognitive effects, tolerance, dependence.
  • Reserve for short-term use or specific situations.

Cyclobenzaprine

  • Mechanism: structurally similar to TCA; not particularly anti-spastic.
  • Useful for: musculoskeletal pain with muscle spasm.
  • NOT effective for true UMN spasticity.

Cannabinoids

  • Nabiximols (Sativex): oromucosal spray; approved in some markets for MS spasticity.
  • Synthetic cannabinoids: limited data.
  • Not FDA-approved for spasticity in US.

Focal Spasticity: Botulinum Toxin

  • First-line for focal spasticity (FDA-approved post-stroke, cerebral palsy).
  • OnabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotulinumtoxinB.
  • Doses to individual muscles: substantial doses may be needed (>400 units for spasticity).
  • EMG/ultrasound guidance.
  • Every 12-16 weeks.
  • Combine with stretching, PT.
  • Useful for: spastic equinus, spastic clubfoot, post-stroke upper limb, post-stroke lower limb, cerebral palsy.

Intrathecal Baclofen Pump

Indication

  • Severe disabling spasticity refractory to oral therapy.
  • Patient appropriate for surgical implantation.
  • SCI, MS, cerebral palsy primary indications.

Procedure

  • Test dose intrathecal baclofen pre-implantation.
  • Pump implanted SC; catheter into intrathecal space.
  • Programmable; doses tailored.

Advantages

  • Much smaller doses (μg vs mg) → less sedation.
  • Improved spasticity vs oral.
  • Functional gains possible.

Complications

  • Pump malfunction.
  • Catheter dysfunction.
  • Infection.
  • Withdrawal syndrome: life-threatening; sudden hyperthermia, rebound spasticity, hallucinations, seizures; needs emergency oral baclofen restart and urgent pump evaluation.
  • Overdose: hypotonia, respiratory depression.
  • Need for refills every 3-6 months.

Surgical / Interventional Options

  • Selective dorsal rhizotomy: for cerebral palsy, severe spasticity.
  • Orthopedic procedures: tendon lengthening, joint releases.
  • Nerve blocks: phenol or alcohol (less commonly used now).

Specific Conditions

Post-Stroke Spasticity

  • Botulinum toxin: focal upper or lower limb.
  • Oral antispasticity: baclofen, tizanidine.
  • Avoid oversedation.
  • PT/OT critical.

Multiple Sclerosis Spasticity

  • Baclofen first-line; intrathecal for severe.
  • Tizanidine alternative.
  • Cannabinoids (where approved).
  • Botulinum toxin for focal.
  • Dalfampridine improves walking via different mechanism.

Spinal Cord Injury Spasticity

  • Baclofen oral or intrathecal (most common indication for ITB).
  • Tizanidine.
  • Botulinum toxin for focal.

Cerebral Palsy

  • Botulinum toxin for focal in children.
  • Selective dorsal rhizotomy for severe diplegic CP.
  • Intrathecal baclofen for severe.
  • Baclofen, tizanidine oral.

Rigidity in PD vs Spasticity

  • PD rigidity: lead-pipe; not velocity-dependent.
  • Spasticity: velocity-dependent; UMN lesion.
  • Treatment differs entirely: dopaminergic for PD rigidity; antispastic for UMN spasticity.

Dystonia vs Spasticity

  • Dystonia: involuntary contracting movements/postures.
  • Spasticity: tone increase.
  • Can coexist; treatment may overlap (botulinum toxin, baclofen).

Painful Spasms

  • SCI: tonic spasms common; gabapentin, baclofen.
  • MS: painful tonic spasms; carbamazepine, gabapentin, baclofen.

Pediatric Spasticity Considerations

  • Different goals: encourage motor development.
  • Multidisciplinary care.
  • Botulinum toxin pediatric doses.
  • Orthopedic management.
  • ITB pumps in selected pediatric patients.

🔍 Did You Know?

The recognition that intrathecal baclofen withdrawal is a life-threatening medical emergency has been a critical patient safety advance in spasticity management. Patients with ITB pumps receive μg quantities of baclofen directly to the CNS, achieving dramatic spasticity reduction with minimal systemic effects. However, pump failure (battery depletion, catheter kinking, programming error, refill error) leads to sudden cessation of CNS baclofen delivery and can produce a withdrawal syndrome with: high fever, severely rebound spasticity, autonomic instability, hallucinations, seizures, and even death. The syndrome can begin within hours of pump failure. The clinical implications: any patient with an ITB pump who presents acutely with fever, altered mental status, or worsening spasticity requires immediate evaluation for pump dysfunction. Treatment includes: (1) urgent restart of oral baclofen (or IV cyproheptadine while waiting); (2) urgent imaging of the pump and catheter; (3) urgent involvement of the ITB team and possibly neurosurgery; (4) supportive care for autonomic instability. The lesson generalizes: any implanted device with continuous drug delivery presents risks if delivery is interrupted, and patient/family education about device complications is critical. For practicing neurologists, ITB pump patients require system-level care coordination — patients must know to seek immediate care if pump issues are suspected, and emergency departments must know how to evaluate. The same principle applies to other implanted drug delivery systems (intrathecal morphine pumps, etc.).

Pitfalls and Pearls

  • Baclofen: GABA-B agonist; first-line; oral or intrathecal.
  • Baclofen withdrawal: life-threatening emergency; ITB pump failure.
  • Tizanidine: α2 agonist; alternative; LFT monitoring; ciprofloxacin interaction.
  • Dantrolene: peripheral; hepatotoxicity risk; better for cerebral-origin spasticity.
  • Diazepam: effective but tolerance, dependence.
  • Cyclobenzaprine: NOT effective for UMN spasticity.
  • Botulinum toxin: focal spasticity first-line; EMG/ultrasound guidance.
  • ITB pump: severe refractory spasticity; SCI, MS, CP.
  • Selective dorsal rhizotomy: pediatric CP, severe spasticity.
  • Cannabinoids (nabiximols): MS spasticity in some markets.
  • Productive spasticity: assess before treating; some spasticity is functional.
  • Multidisciplinary: PT, OT essential.
  • Post-stroke: combine focal botulinum with oral.
  • MS spasticity: baclofen + dalfampridine.
  • SCI tonic spasms: gabapentin, baclofen.
  • Avoid oversedation: limits PT progress.

References

  1. Simpson DM, Gracies JM, Yablon SA, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80(4):380-385.
  2. Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene—a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364-373.
  3. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83(6):735-741.
  4. Boudokhane S, Janse van Rensburg A, Stagg P. Treatment of spasticity—recent advances. Curr Treat Options Neurol. 2020;22(7):20.
  5. Plassat R, Verbe BP, Menei P, et al. Effectiveness of intrathecal baclofen on autonomic dysreflexia. Spinal Cord. 2011;49(1):28-32.